We have characterized the molecular basis of the interaction between ASPP2 and Bcl-2, which are key proteins in the apoptotic pathway. The C-terminal ankyrin repeats and SH3 domain of ASPP2 (ASPP2 Ank-SH3) mediate its interactions with the antiapoptotic protein Bcl-2. We used biophysical and computational methods to identify the interaction sites of Bcl-2 and its homologues with ASPP2. Using peptide array screening, we found that ASPP2 Ank-SH3 binds two homologous sites in all three Bcl proteins tested: (i) the conserved BH4 motif, and (ii) a binding site for proapoptotic regulators. Quantitative binding studies revealed that binding of ASPP2 Ank-SH3 to the Bcl-2 family members is selective at two levels: (i) interaction with Bcl-2-derived peptides is the tightest compared to peptides from the other family members, and (ii) within Bcl-2, binding of ASPP2 Ank-SH3 to the BH4 domain is tightest. Sequence alignment of the ASPP2-binding peptides combined with binding studies of mutated peptides revealed that two nonconserved positions where only Bcl-2 contains positively charged residues account for its tighter binding. The experimental binding results served as a basis for docking analysis, by which we modeled the complexes of ASPP2 Ank-SH3 with the full-length Bcl proteins. Using peptide arrays and quantitative binding studies, we found that Bcl-2 binds three loops in ASPP2 Ank-SH3 with similar affinity, in agreement with our predicted model. Based on our results, we propose a mechanism in which ASPP2 induces apoptosis by inhibiting functional sites of the antiapoptotic Bcl-2 proteins.
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apoptosis ͉ peptides ͉ protein-protein interactions ͉ peptide arrays ͉ docking P rotein-protein interactions (PPI) are crucial for most processes critical for the proper function of living cells. Studying PPI is important for understanding the cell functionality and for designing drugs against diseases in which PPI are impaired. Peptides are excellent tools for studying PPI. They are good models for binding studies of protein domains because they often undergo induced fit upon ligand binding and gain their native structure. This was shown for peptides derived from the BH4 domain of Bcl-2 (1) and from Bak (2). Peptide arrays provide an efficient way for identifying binding sites (3). Peptide arrays were particularly valuable for epitope mapping and analyzing enzyme binding and PPI (4-7).
Impairment of regulation of apoptosis pathways is a key event in malignant transformation. Understanding how apoptotic pathways are regulated is essential to understanding the basics for developing anticancer therapies. Two key apoptotic pathways are the p53 pathway and the mitochondrial death pathway. We used the peptide approach to characterize the interaction between two key players in these apoptotic pathways: ASPP2 and the Bcl-2 family proteins.
Proteins from the Bcl-2 family play a major role in the mitochondrial death pathway (8). The Bcl-2 family consists of both proapoptotic (e.g., Bax and Bak) and antiapoptotic (e.g., Bcl-2, Bcl-X L , and Bcl-W) members, which cooperate through formation of homo-/heterodimers that maintain the balance between cell death and survival. The antiapoptotic proteins inhibit apoptosis in normal cells, but in response to apoptotic signals, the proapoptotic family members mediate the release of cytochrome C (reviewed in refs. 8 and 9). Inhibition of antiapoptotic Bcl-2 family members is a major target for anticancer therapies (10).
The ASPP2 protein specifically stimulates the apoptotic response mediated by the tumor suppressor p53, by enhancing the transactivation function of p53 on promoters of proapoptotic genes (11). Two ASPP2 variants were discovered as p53 and Bcl-2 binding proteins: 53BP2 and Bbp, respectively (12) [supporting information (SI) Fig. S1 ]. ASPP2 contains several structural and functional domains (Fig. S1) (13, 14) . The C-terminal part of ASPP2 contains four ankyrin repeats and an SH3 domain (ASPP2 Ank-SH3 ) (15), which mediate its interactions with numerous apoptosis-related partner proteins such as p53, NFB, and Bcl-2 (13). ASPP2 and Bbp are predominantly localized in the cytoplasm, whereas Bbp is partly localized in the mitochondria and is involved in the mitochondrial death pathway (16). Expression of both Bcl-2 and Bcl-X L inhibited Bbp-induced cell death (17), suggesting that the ASPP2-Bcl complex may maintain the balance between the pro-and antiapoptotic activity of both proteins.
Here, we used a combination of peptide arrays with biophysical and computational methods to gain insight into regulation of apoptosis by studying the molecular basis of the interactions between the antiapoptotic proteins from the Bcl-2 family and the proapoptotic protein ASPP2. We identified the sites that mediate the interactions in both the Bcl proteins and ASPP2 Ank-SH3 , and gained insight into the molecular mechanism of the interaction. Using docking studies supported by experimental data, we suggest a model for the complex between the full-length ASPP2 Ank-SH3 and Bcl-2/Bcl-X L . We propose that ASPP2 binds and inhibits functional sites of antiapoptotic Bcl-2 proteins, promoting the release of proapoptotic proteins and the induction of apoptosis.
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